Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| BIVA | MXN | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
AstraZeneca Plc (NASDAQ: AZN) released data from the Phase 3 ALPHA trial of danicopan as an add-on to the standard of care for paroxysmal nocturnal hemoglobinuria (PNH). The data...
AstraZeneca plc (NASDAQ: AZN) has entered into a collaboration, exclusive option, and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg)...
Proactive Investors - AstraZeneca PLC (LON:AZN) is placing an US$85mln bet on the autoimmune cell therapy sector with Quell Therapeutics - its latest licensing partner. As well as...
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales....
AstraZeneca (NASDAQ:AZN) Plc (LSE:AZN) shares are listed on the London Stock Exchange. But it’s worth noting that the company has a dual listing on the Nasdaq in the United...
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 5.25 | 5.25 | 5.25 | 0.00 | 0.00% | 298.34K | London | |||
| 0.60 | 0.60 | 0.60 | 0.00 | 0.00% | 0.00 | London | |||
| 0.40 | 0.407 | 0.382 | 0.00 | 0.00% | 0.00 | London | |||
| 250.00 | 250.00 | 250.00 | 0.00 | 0.00% | 0.00 | London | |||
| 195.00 | 195.00 | 195.00 | 0.00 | 0.00% | 0.00 | London | |||
| 6.75 | 6.80 | 6.80 | 0.00 | 0.00% | 142.65K | London | |||
Warner Estatederived | 0.93 | 0.925 | 0.925 | 0.00 | 0.00% | 0.00 | London | ||
| 264.50 | 265.50 | 262.50 | 0.00 | 0.00% | 492.15K | London | |||
| 53.50 | 53.50 | 53.50 | 0.00 | 0.00% | 0.00 | London | |||
| 1.40 | 1.40 | 1.40 | 0.00 | 0.00% | 0.00 | London | |||
| 317.50 | 320.00 | 320.00 | 0.00 | 0.00% | 0.00 | London | |||
| 1.125 | 1.125 | 1.125 | 0.00 | 0.00% | 0.00 | London | |||
| 14.30 | 14.30 | 14.30 | +11.11 | +347.85% | 334.19K | London | |||
| 521.50 | 524.00 | 516.00 | +2.00 | +0.39% | 204.06K | London | |||
| 39.00 | 39.00 | 39.00 | 0.00 | 0.00% | 0.00 | London |